. . . "25381"^^ . "26190"^^ . . "2"^^ . . "Podrobnosti o hlavn\u00EDch studi\u00EDch, v\u010Detn\u011B popis\u016F studi\u00ED a hlavn\u00EDch v\u00FDsledk\u016F t\u00FDkaj\u00EDc\u00EDch se \u00FA\u010Dinnosti, jsou uvedeny v bod\u011B 5.1. \nNej\u010Dast\u011Bji hl\u00E1\u0161en\u00FDmi a/nebo klinicky relevantn\u00EDmi ne\u017E\u00E1douc\u00EDmi \u00FA\u010Dinky l\u00E9\u010Diva byly gastrointestin\u00E1ln\u00ED obt\u00ED\u017Ee (zejm\u00E9na pr\u016Fjem, nauzea, zvracen\u00ED, bolesti b\u0159icha a stomatitida), syndrom ruka-noha (palm\u00E1rn\u011B-plant\u00E1rn\u00ED erytrodysest\u00E9zie), \u00FAnava, ast\u00E9nie, anorexie, kardiotoxicita, zhor\u0161en\u00ED ren\u00E1ln\u00ED dysfunkce u preexistuj\u00EDc\u00ED poruchy ren\u00E1ln\u00EDch funkc\u00ED a tromboembolismus. \nb.Tabulkov\u00E9 shrnut\u00ED ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F \nNe\u017E\u00E1douc\u00ED \u00FA\u010Dinky pova\u017Eovan\u00E9 vy\u0161et\u0159uj\u00EDc\u00EDmi za mo\u017En\u00E1, pravd\u011Bpodobn\u011B nebo vzd\u00E1len\u011B souvisej\u00EDc\u00ED s pod\u00E1v\u00E1n\u00EDm kapecitabinu jsou shrnuty v tabulce 4 pro kapecitabin pod\u00E1v\u00E1n\u00FD samostatn\u011B a v Tabulce 5 pro kapecitabin pod\u00E1van\u00FD v kombinaci s r\u016Fzn\u00FDmi re\u017Eimy chemoterapie v rozli\u010Dn\u00FDch indikac\u00EDch."@cs . . . . . . . . .